In today’s podcast Crinetics cofounders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, and share what it really takes to bring a new medication from concept to patients. This is a rare, candid look inside a complex industry that you won’t want to miss. Drs. Struthers and Betz are both frequent guests of Pituitary World News. We are please to welcome them to the Adrenal World News podcast and their discussion about two drugs for CAH and ACTH Dependent Cushing’s syndrome. Listen as they talk about their new drug under development Atumelnant, which is the first investigational once-daily, oral MC2R antagonist that selectively blocks the activity of ACTH at the adrenal cortex. Atumelnant was designed to help patients combat the effects of over-secretion of ACTH.
If you’d like to listen to some of the past chats please click on the links below .
- This is a fascinating chat with Scott in 2017 when CRN808, now Palsonify®, was entering clinical trials.
- This podcast from January 2020, recorded late in 2019, was the first in a series of 6 podcasts on the ins and outs of drug development and will give you a perspective of where Crinetics was 6 years ago.
If you found this conversation and our content valuable, please share it with your friends, family, and healthcare providers. Too many people with pituitary and adrenal diseases wait years for an accurate diagnosis. By raising awareness together, we can help more patients get the care they need sooner.
Click on this link for more information on Atumelnant clinical trial for Congenital Adrenal Hyperplasia (CAH)
Watch the video of the podcasts
© 2026, AWN. All rights reserved.